WallStSmart

Intellicheck Mobilisa Inc (IDN)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 1042% more annual revenue ($258.90M vs $22.67M). IDN leads profitability with a 5.6% profit margin vs -15.5%. IDN earns a higher WallStSmart Score of 55/100 (C-).

IDN

Buy

55

out of 100

Grade: C-

Growth: 8.0Profit: 5.0Value: 4.7Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IDNUndervalued (+8.3%)

Margin of Safety

+8.3%

Fair Value

$5.19

Current Price

$7.99

$2.80 discount

UndervaluedFair: $5.19Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IDN2 strengths · Avg: 9.0/10
EPS GrowthGrowth
230.6%10/10

Earnings expanding 230.6% YoY

Operating MarginProfitability
22.5%8/10

Strong operational efficiency at 22.5%

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

IDN4 concerns · Avg: 2.8/10
Market CapQuality
$160.50M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

Profit MarginProfitability
5.6%3/10

5.6% margin — thin

P/E RatioValuation
113.3x2/10

Premium valuation, high expectations priced in

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : IDN

The strongest argument for IDN centers on EPS Growth, Operating Margin. Revenue growth of 11.8% demonstrates continued momentum. PEG of 1.31 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : IDN

The primary concerns for IDN are Market Cap, Return on Equity, Profit Margin. A P/E of 113.3x leaves little room for execution misses.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

IDN profiles as a value stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

IDN scores higher overall (55/100 vs 41/100) and 11.8% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intellicheck Mobilisa Inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Intellicheck, Inc., a technology company, develops, integrates and markets threat identification and identity authentication solutions for retail and banking fraud prevention, law enforcement threat identification, and mobile security and access control systems and laptops, primarily in the United States. The company is headquartered in Melville, New York.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?